Navigation Links
ThromboGenics N.V. - Business Update
Date:5/13/2008

s trial will be presented by the lead investigator, Prof. Peter Stalmans, at the Euretina Conference on May 23, in Vienna. The third and fourth cohorts from this trial will be presented at major ophthalmic conferences in the second half of 2008.

- Results are expected from the Phase II MITI IV trial in mid 2008.

This Phase II trial is evaluating the safety and preliminary efficacy of microplasmin when administered intravenously to acute stroke patients. Once these data from the study have been reviewed, a decision will be made on the future development plans for microplasmin in the treatment of acute stroke.

It is ThromboGenics' current intention that it will only move forward with the development of microplasmin for the treatment of stroke in conjunction with a partner. This intention is based on both the risks and cost associated with the development of new stroke therapies and the Company's desire to invest in its other attractive pipeline product candidates, such as microplasmin in the treatment of back of the eye diseases and TB-403.

TB-403

- Results from the initial Phase I trial of this novel anti-cancer agent in healthy volunteers are expected in the third quarter of 2008.

Following the successful completion of this initial Phase I study, ThromboGenics expects to begin a Phase Ib trial with TB-403 in end stage cancer patients in mid 2008. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients and some early efficacy data on the product.

TB-402

- Top line results of the interaction studies to be announced by mid-2008.

TB-402 is being developed as an anti-coagulant for the prevention of deep vein thrombosis (DVT) after orthopaedic surgery and prevention of venous emboli in patients with atrial fibrillation. It is a novel human antibody that partially blocks Factor VIII, an essential blood clotting factor. The implicat
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
11. DuPont Leaders Brief Investors on Agriculture Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... of building materials using light, developed by researchers at ... that are often considered the realm of science fiction, ... Although cloaked starships won,t be a reality for quite ... constructing materials with building blocks a few billionths of ... way that light flies through them, and works on ...
(Date:7/28/2014)... According to a new market research report published ... Joint) Market (By Technology - Stem Cell Therapy, ... Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic Products ... Growth, Trends and Forecast, 2013 - 2019" the ... valued at USD 2.6 billion in 2012 and ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... 28, 2014 Appistry, Inc. , ... bring the power of genomics to next-generation medicine, announced ... Pipeline Challenge . , Two Appistry staff will ... National Center for Genome Resources, and Mr. Neil Miller, ... of Kansas City. Rounding out the panel are Appistry’s ...
Breaking Biology Technology:Building 'invisible' materials with light 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2
... Professor James Dumesic, graduate students Steven T. Evans, Tobias ... Kim. Source: UW-Madison. MADISON - Carbon monoxide, or ... the efficient operation of fuel cells. But now, chemical ... not only cleared that barrier - they also have ...
... competitors can copy the newest product enhancement, advertising ... process seemingly overnight. Indeed, it seems that no ... realization has led many corporate leaders to conclude ... is to create organizations that can respond fast ...
... General Electric Company , announced Monday it has developed ... increase efficiency for physicians. , ,The new visual stethoscope, ... larger-scale systems but in a portable and wireless design ... possible for patients to receive diagnostic exams anywhere, including ...
Cached Biology Technology:UW engineers clear bottleneck in hydrogen production 2Going beyond me, too customer experiences 2Going beyond me, too customer experiences 3Going beyond me, too customer experiences 4GE Healthcare announces new, high-tech 'stethoscope' 2
(Date:7/28/2014)... Children,s Research Hospital study found that 73 percent of ... risk of developing metabolic syndrome and related health problems ... appear in the current issue of the journal ... adult survivors of childhood cancer in the study had ... like high blood pressure, abdominal obesity, elevated triglyceride and ...
(Date:7/28/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... analyze biological data. These systems capture biological traits such ... and hand measurements from the subject and compare the ... purpose of a biometrics system is to identify and ...
(Date:7/28/2014)... Researchers using statistical tools to map social connections ... traditional observational techniques, shedding light on prairie dog ... bubonic plague and guide future conservation efforts. The ... State University and the National Evolutionary Synthesis Center ... are subject to bubonic plague," says Dr. Jennifer ...
Breaking Biology News(10 mins):Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3Biometrics Market in Latin America 2014-2018 2Social network research may boost prairie dog conservation efforts 2
... -- Chronic water quality problems caused by agricultural ... the burning of fossil fuels leads to oxygen depletion, ... pollution is prevalent in many coastal marine and estuarine ... North America and although many efforts have been taken ...
... has revealed the mechanism that binds skin cells tightly ... for painful and debilitating skin diseases and also lethal ... of Life Sciences, has found that the glue molecules ... making a very tough, resilient structure. Further investigation on ...
... can be an opportunity for researchers to foster respectful ... This shift is proposed in a policy forum appearing ... of the American Academy for the Advancement of Science. ... Practices and Participant Preferences: The Growing Gulf" recommend new ...
Cached Biology News:Could oysters be used to clean up Chesapeake Bay? 2Cell binding discovery brings hope to those with skin and heart problems 2Gulf grows between research practice and participant preferences in genetic studies 2Gulf grows between research practice and participant preferences in genetic studies 3Gulf grows between research practice and participant preferences in genetic studies 4
... Adhesion Molecule The L1CAM ... involved in three distinct conditions: 1) HSAS ... MASA (mental retardation, aphasia, shuffling gait, adductus ... Immunogen: Homogenous suspension of ...
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... PP2A1, purified Formulation: 50mM ... 0.02% Brij-35, 0.2mM PMSF, 1mM ... glycerol. Properites: PP2A1 (Protein Phosphatase ... DEAE-Sephadex, ammonium sulfate precipitation, QSepharose,amino-hexyl ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: